Nimbolide and Azadirachta Indica Applications in Oncological and Metabolic Disorders

Nimbolide, a limonoid extracted from the leaves of Azadirachta indica (Neem), has emerged as a multifaceted bioactive compound with significant promise in both oncology and metabolic disease management. In cancer research, nimbolide exhibits potent antiproliferative activity across a range of malignancies, including pancreatic, oral and bone cancers. Its mechanisms of action encompass induction of reactive oxygen species (ROS), modulation of apoptotic and autophagy pathways, inhibition of epithelial-to-mesenchymal transition and suppression of angiogenesis. Parallel investigations into the broader phytochemistry of Neem have revealed that related limonoids, such as gedunin and azadiradione, target carbohydrate-digesting enzymes and inflammatory mediators, offering novel routes to glycaemic control and reduction of metabolic syndrome-associated oxidative stress. Collectively, these findings underscore the global significance of Azadirachta indica as a source of lead compounds for drug development, emphasising its safety profile, low cost and long history of use in traditional medicine.

Research from Nature Portfolio

Recent studies have deepened understanding of nimbolide’s anticancer efficacy in preclinical models. Investigations into pancreatic ductal adenocarcinoma demonstrate that nimbolide triggers excessive ROS generation, leading to mitochondrial-mediated apoptosis without reliance on autophagy. This oxidative assault also downregulates PI3K/Akt/mTOR and ERK signalling cascades, curtailing tumour growth and metastatic potential in vivo. In parallel, work in an established oral carcinogenesis model reveals that nimbolide upregulates the metastasis suppressor RECK by targeting miR-21 and HIF-1α. This action diminishes matrix metalloproteinase activity, blocks VEGF-driven angiogenesis and attenuates Notch pathway signalling, resulting in reduced microvascular density and impaired tumour invasion. These seminal findings illuminate nimbolide’s capacity to orchestrate a coordinated blockade of survival, migratory and angiogenic programmes in cancer cells.

Research from all publishers

Contemporary reports in non-Portfolio journals have expanded the spectrum of nimbolide and Neem derivatives. A 2023 investigation shows that nimbolide silences mitochondrial superoxide dismutase (SOD2) in pancreatic cancer cells, amplifying ROS levels, enhancing apoptosis and suppressing key traits of invasiveness such as colony formation, migration and epithelial-to-mesenchymal transition. In the metabolic realm, bioassays of gedunin and azadiradione from Neem demonstrate mixed-mode inhibition of human pancreatic α-amylase, effectively lowering postprandial glucose peaks in vitro and suggesting utility as antidiabetic leads. An integrative review also highlights Neem extracts’ capacity to modulate inflammatory cytokines, improve insulin sensitivity and protect against oxidative damage in diabetic models, while emphasising the need for standardised extraction protocols to ensure safety and reproducibility.

Nimbolide and Azadirachta Indica Applications in Oncological and Metabolic Disorders publication trend

The graph below shows the total number of articles in nimbolide and azadirachta indica applications in oncological and metabolic disorders across all publications each year (not limited to Nature Index journals).

Technical terms

Limonoid: A class of triterpenoid compounds characteristic of the Meliaceae family, often possessing bioactive properties.

Reactive oxygen species (ROS): Chemically reactive molecules containing oxygen that can induce cellular damage or trigger signalling pathways leading to apoptosis.

Apoptosis: Programmed cell death involving caspase activation and characteristic morphological changes, crucial for removing malignant or damaged cells.

Autophagy: A regulated process of intracellular degradation in which cytoplasmic components are sequestered in autophagosomes and delivered to lysosomes for recycling.

Epithelial-to-mesenchymal transition (EMT): A cellular programme in which epithelial cells acquire motile mesenchymal traits, facilitating invasion and metastasis.

PI3K/Akt/mTOR pathway: A central intracellular signalling network governing cell growth, survival and metabolism, frequently dysregulated in cancer and diabetes.

RECK: A membrane-anchored glycoprotein that inhibits matrix metalloproteinases, thereby restraining tumour invasion and angiogenesis.

Pancreatic α-amylase: An enzyme secreted by the pancreas that breaks down starch into simple sugars, representing a target for controlling postprandial blood glucose levels.

References

1. Nimbolide inhibits pancreatic cancer growth and metastasis through ROS-mediated apoptosis and inhibition of epithelial-to-mesenchymal transition. Scientific Reports (2016).
2. Nimbolide upregulates RECK by targeting miR-21 and HIF-1α in cell lines and in a hamster oral carcinogenesis model. Scientific Reports (2017).
3. Nimbolide Inhibits SOD2 to Control Pancreatic Ductal Adenocarcinoma Growth and Metastasis. Antioxidants (2023).
4. Gedunin and Azadiradione: Human Pancreatic Alpha-Amylase Inhibiting Limonoids from Neem (Azadirachta indica) as Anti-Diabetic Agents. PLOS ONE (2015).
5. Therapeutics Role of Azadirachta indica (Neem) and Their Active Constituents in Diseases Prevention and Treatment. Evidence-based Complementary and Alternative Medicine (2016).
6. Nimbolide Induces ROS-Regulated Apoptosis and Inhibits Cell Migration in Osteosarcoma. International Journal of Molecular Sciences (2015).
7. Nimbolide, a neem limonoid inhibits cytoprotective autophagy to activate apoptosis via modulation of the PI3K/Akt/GSK-3β signalling pathway in oral cancer. Cell Death & Disease (2018).